Stay Up to Date
Breaking News,
Updates, & More
Click Here to

Mutational Load and T-Cell–Inflamed Microenvironment May Predict Response to Pembrolizumab

TOP - May 2017, Vol 10, No 2 - Immunotherapy
Chase Doyle

Orlando, FL—The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains elusive. According to data presented at the 2017 Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium, predictive biomarkers may be close at hand.

Genetic analyses from 2 recent multicohort advanced solid tumor trials suggest that tumor mutational load and tumor T-cell inflammation, measured by gene-expression profiling, are independent determinants of response to anti–PD-1 therapy.

“Nonsynonymous mutational load and neoantigen load, as well as an 18-gene immune-related gene expression profile, were significantly associated with overall response to pembrolizumab across multiple indications. The predicted clinical utility of both mutational load and gene expression profile was similarly high in these cohorts, suggesting comparable individual diagnostic abilities,” said Tanguy Seiwert, MD, Assistant Professor of Medicine, University of Chicago, IL.

“Based on these data, mutational load and gene expression profiling may have utility in characterizing responses to anti–PD-1 and other cancer immunotherapies,” he added.

As Dr Seiwert reported, tumor mutational load has been shown to correlate with benefit from CTLA-4 and PD-1 immunotherapies in multiple tumor types, including melanoma, non–small-cell lung cancer, colorectal cancer, and urothelial cancer. At the same time, tumor T-cell inflammation, which correlates with T-cell infiltration, gamma interferon expression, and PD-L1 and PD-L2 expression, has been advanced as an alternative biomarker.

Using data from 2 multicenter, multicohort studies (KEYNOTE-012 and KEYNOTE-028), Dr Seiwert and colleagues examined the association between mutational load and progression-free survival in 153 patients with PD-L1–positive tumors—21 different tumor types—who had whole-exome sequencing available. Overall response was also evaluated in patients with whole-exome sequencing and measurable disease at baseline (n = 135). For tumor T-cell inflammation, expression values for 18 genes were used to determine whether the tumor was inflamed. Finally, the association between mutational load and gene-expression profiling was also explored in Moffitt and The Cancer Genome Atlas data sets.

According to Dr Seiwert, objective response to treatment was significantly associated with mutational load (P = .0001), neoepitope load (P = .0001), and gene-expression profile (P = .0004). More specifically, at a mutational load cutoff of 102, response rates exceeded 30% in patients with ≥102 mutations. For patients with tumors carrying <102 mutations, however, response rates dropped to 7%.

Gene-expression profiling was also significantly associated with overall survival (P = .0071). In addition, patients with more inflamed tumors had a response rate of 25%, compared with a response rate of only 2% for patients with noninflamed tumors.

Finally, in patients with high mutational load and tumor inflammation, response rates exceeded 38%. In patients with low mutational load and noninflamed tumors, however, response rates fell to 0%.

“Mutational load and tumor T-cell inflammation are common features of anti–PD-1 responsive tumors. Whether used separately or in combination, these markers appear to have a high positive and negative predictive value, and may have clinical utility,” Dr Seiwert concluded.

Related Items
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer
Phoebe Starr
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer, Immunotherapy
FDA Perspective: Reducing Cost, Increasing Access to Cancer Care
Chase Doyle
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Health Policy
Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma
Wayne Kuznar
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Immunotherapy, Renal-Cell Carcinoma
Nivolumab–Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Immunotherapy
Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer
Chase Doyle
TOP - November 2018, Vol 11, No 3 published on November 21, 2018 in HOPA 2018 Highlights
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Web Exclusives published on October 9, 2018 in Immunotherapy, Multiple Myeloma
Discussing Costs with Your Patient Can Reduce Financial Toxicity
Chase Doyle
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Best Practices
Last modified: May 10, 2017